Trial Profile
A retrospective, observational study of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2017
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions
- 08 Dec 2017 Results published in the American Journal of Cardiovascular Drugs
- 26 Feb 2016 New trial record